Status:
UNKNOWN
Investigational Biomarkers for Neurological Immune-related Adverse Events
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Neurological Disease
Eligibility:
All Genders
18+ years
Brief Summary
Neurological immune-related adverse events (n-irAEs) are an emerging group of disorders of patients with cancer treated with immune checkpoint inhibitors, presenting with heterogeneous clinical manife...
Eligibility Criteria
Inclusion
- Clinical diagnosis of n-irAEs
Exclusion
- Presence of an alternative diagnosis explaining the neurological syndrome
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05969379
Start Date
May 1 2022
End Date
December 1 2023
Last Update
August 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes, Hôpital neurologique Pierre Wertheimer
Bron, France, 69500